Table 2.
Patients, their disease and transplantation and transplant center practices
| Variable |
Group 1 Automated processing plasma and red cell reduced or buffy coat production method |
Group 2 Manual processing plasma and red cell reduced or buffy coat production method |
Group3 Manual processing plasma reduced |
P-value |
|---|---|---|---|---|
| Number of patients | 118 | 279 | 133 | |
| Age | 0.47 | |||
| ≤16 years | 89 (75) | 225 (81) | 107 (80) | |
| >16 years | 29 (25) | 54 (19) | 26 (20) | |
| Sex | 0.76 | |||
| Male | 55 (47) | 141 (51) | 67 (50) | |
| Female | 63 (53) | 138 (46) | 66 (50) | |
| Performance score | 0.21 | |||
| <90 | 20 (17) | 51 (18) | 33 (25) | |
| 90 – 100 | 97 (82) | 218 (78) | 97 (73) | |
| Not reported | 1 (<1) | 10 (4) | 3 (2) | |
| Recipient CMV serostatus | 0.06 | |||
| Negative | 46 (39) | 137 (49) | 53 (40) | |
| Positive | 71 (60) | 137 (49) | 79 (59) | |
| Not reported | 1 (<1) | 5 (1) | 1 (1) | |
| Recipient race | <0.001 | |||
| Caucasian | 61 (52) | 181 (65) | 55 (41) | |
| Non-Caucasian | 57 (48) | 92 (33) | 77 (58) | |
| Not reported | 0 | 6 (2) | 1 (<1) | |
| Disease status at transplant | 0.02 | |||
| CR1/RA | 52 (44) | 92 (33) | 53 (40) | |
| CR2 | 53 (45) | 127 (46) | 48 (36) | |
| Relapse/RAEB | 13 (11) | 60 (21) | 32 (24) | |
| Conditioning regimen | 0.04 | |||
| TBI-containing | 96 (81) | 193 (69) | 100 (75) | |
| Non-TBI containing | 22 (19) | 86 (31) | 33 (25) | |
| GVHD prophylaxis | 0.26 | |||
| Tacrolimus-containing | 33 (28) | 77 (28) | 47 (35) | |
| Cyclosporine-containing | 83 (70) | 199 (71) | 85 (64) | |
| Other | 2 (2) | 3 (1) | 1 (1) | |
| HLA match low resolution at A, B, and allele-level DRB1 | 0.42 | |||
| 4/6 | 42 (36) | 88 (32) | 55 (41) | |
| 5/6 | 57 (48) | 141 (51) | 58 (44) | |
| 6/6 | 19 (16) | 50 (17) | 20 (15) | |
| Donor recipient race match | 0.02 | |||
| Donor recipient same race | 71 (60) | 150 (54) | 70 (53) | |
| Donor recipient different race | 47 (40) | 72 (26) | 62 (47) | |
| Unknown | 0 | 57 (20) | 1 (1) | |
| In vivo T depletion | <0.001 | |||
| No | 76 (64) | 116 (42) | 58 (44) | |
| Yes | 42 (36) | 163 (58) | 75 (56) | |
| Total nucleated cells (107/kg) | ||||
| ≤3.0 | 11 (9) | 32 (11) | 17 (13) | 0.01 |
| 3.0 – 5.0 | 44 (37) | 74 (27) | 24 (18) | |
| > 5.0 | 61 (52) | 172 (62) | 92 (69) | |
| Not reported | 2 (2) | 1 (<1) | 0 | |
| Post-thaw total nucleated cells recovery | 0.77 | |||
| <70% | 21 (18) | 56 (20) | 27 (20) | |
| 70% – 90% | 53 (45) | 120 (43) | 62 (47) | |
| >90% | 23 (19) | 67 (24) | 28 (21) | |
| Not reported | 21 (18) | 36 (13) | 16 (12) | |
| Thawing method at transplant center | <0.001 | |||
| No Wash/DMSO dilution | 44 (37) | 42 (15) | 24 (18) | |
| Washed, reconstituted in dextran/hespan/plasmalyte | 71 (60) | 219 (78) | 95 (71) | |
| Not reported | 3 (3) | 17 (7) | 14 (11) | |
| Interval between thaw to completing of infusion | 0.62 | |||
| <2 h | 38 (32) | 91 (33) | 45 (34) | |
| 2 – 4 h | 56 (47) | 127 (46) | 56 (42) | |
| >4 h | 11 (9) | 32 (11) | 22 (17) | |
| Not reported | 13 (11) | 29 (10) | 10 (8) | |
| Interval from unit collection to transplant | <0.001 | |||
| ≤1 y | 27 (23) | 22 (8) | 21 (16) | |
| 1–3 y | 64 (54) | 97 (35) | 48 (36) | |
| 3–5 y | 19 (16) | 76 (27) | 33 (25) | |
| >5 y | 8 (7) | 84 (30) | 31 (23) | |
| Planned growth factor therapy | 0.02 | |||
| None | 34 (29) | 87 (31) | 60 (45) | |
| Yes | 68 (58) | 152 (54) | 52 (39) | |
| Not reported | 16 (14) | 40 (15) | 21 (16) | |
| Year of transplant | <0.001 | |||
| 2000–2004 | 6 (5) | 57 (20) | 21 (16) | |
| 2005–2011 | 112 (95) | 222 (80) | 112 (84) |